AADI Aadi Bioscience, Inc.
Latest News

$4.180.16 (+3.98%)3:56 PM 10/04/23

NASDAQ | $USD | Realtime

News

Show Full Stories

This feature available only for pro users

Type:

Date Range:

Aadi Bioscience appoints Dave Lennon Ph.D. as chief executive officer

Aadi Bioscience GAAP EPS of -$0.67 misses by $0.07, revenue of $6.2M misses by $0.11M

Aadi Bioscience Q2 2023 Earnings Preview

Aadi Bioscience GAAP EPS of -$0.57 beats by $0.03, revenue of $5.9M beats by $0.42M

Aadi Bioscience Q1 2023 Earnings Preview

Aadi Bioscience GAAP EPS of -$0.52 beats by $0.19, revenue of $5.23M beats by $0.58M

Aadi Bioscience Q4 2022 Earnings Preview

Aadi Bioscience CEO Brendan Delaney resigns

Aadi Bioscience GAAP EPS of -$0.68, revenue of $4.24M

Aadi Bioscience names CEO Neil Desai as executive chairman

Aadi Bioscience highlights combination of KRAS inhibitors and nab-sirolimus for tumors

Aadi Bioscience gets $75M private placement financing

Aadi Bioscience GAAP EPS of -$0.87, revenue of $3.43M

Aadi Bioscience to enter Russell 2000 and Russell 3000 indexes

Aadi Bioscience GAAP EPS of -$0.66, revenue of $2.31M

Aadi Bioscience GAAP EPS of -$0.77, revenue of $1M

Aadi Bioscience launches rare cancer therapy Fyarro

Aadi Bioscience wins FDA approval for rare cancer therapy

Aadi Bioscience reports Q3 results

Aadi Bioscience rises on CFO appointment

Aadi Bioscience highlights publication of data analysis from ABI-009 cancer trial

Aadi Bioscience appoints Brendan Delaney as COO

Aadi Bioscience appoints Brendan Delaney as COO

Aadi Bioscience closes merger with Aerpio Pharmaceuticals and $155M private placement

Aerpio Pharms EPS beats by $0.31

DPW, ANVS and CFMS among pre market gainers

Alector leads weekly healthcare gainers; gene-editing stocks fall after Intellia-driven rally

Galectin Therapeutics, ReShape Lifesciences leads healthcare gainers; Sigilon Therapeutics, Aerpio Pharmaceuticals among major losers

Talkspace and 9 Meters initiated as outperform, and Cantor bullish on COMPASS in today's analyst action

BriaCell Therapeutics, Constellation Pharmaceuticals leads healthcare gainers; iRhythm Technologies, Progenity among major losers

Aerpio slips after Aadi Bioscience updated data for cancer agent nab-sirolimus

Aerpio releases data claiming COVID drug protects against blood vessel dysfunction

Aerpio Pharms EPS beats by $0.01

Aerpio Pharma shares surge 20% on merger deal with Aadi Bioscience

Aerpio Pharms EPS beats by $0.04

Quantum halts testing Aerpio Pharmaceuticals' razuprotafib in COVID-19 setting

Aerpio launches process to explore strategic alternatives

Aerpio announces results from Razuprotafib Glaucoma Phase 2 Trial

Aerpio Pharms EPS beats by $0.02

Mid-stage study of Aerpio's razuprotafib for COVID-19 underway

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.

Is this happening to you frequently? Please report it on our feedback forum.

If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.